Perjeta US OK tops winning week for Genentech/Roche in breast cancer
This article was originally published in Scrip
Topping off a successful week of having some of the most talked about data in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO) with the experimental "smart bomb" drug T-DM1 in HER2-positive metastatic breast cancer, Roche and its US unit Genentech gained the US FDA's approval on 8 June to market Perjeta (pertuzumab) as a therapy to treat the disease.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.